Corteva, Inc. · CTVA · FY2026 Q1 · Calendar Q2 2026

Corteva Q1 2026: EBITDA Jumps 21% as Royalty Positivity Arrives Early

Corteva delivered a strong start to fiscal 2026, beating consensus on both EPS ($1.50 vs. $1.17 estimate, 28% surprise) and revenue ($4.91B vs. $4.64B estimate, 5.7% surprise). Q1 EBITDA grew 21% year-over-year with margins above 29%, driven by solid performance across both seed and crop-protection segments. The company reaffirmed its full-year 2026 operating EBITDA guidance of $4.0 to $4.2B with 22 to 23% margins. A notable milestone: Corteva now expects to achieve royalty positivity this year, ahead of its prior royalty-neutral timeline, thanks to the Bayer licensing agreement. The planned separation into Vylor (seed) and a standalone crop-protection business remains on track for Q4 2026, with a Form 10 filing expected by Q2. Despite the strong quarter, the stock sold off post-earnings with a -3.9% abnormal move and -5.3% subsequent drift, potentially reflecting concerns over H2…

Reported After market closeNYSEBasic Materials $59.51B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $1.50 Consensus $1.17
EPS surprise +28.2% Reported versus consensus
Reported revenue $4.91B Consensus $4.64B
Revenue surprise +5.7% Reported versus consensus

Market reaction

event-close to next-session close
Stock move -2.5% Event window
SPY move +1.4% Same window
Abnormal move -3.9% Stock minus SPY
Volume 1.7× Versus trailing sessions
Subsequent drift -5.3% Up to 20 sessions
CTVASPY benchmark

Ask FN2 about CTVA FY2026 Q1

Transcript, numbers and history already loaded
Why did CTVA fall 2.5% after beating EPS estimates in FY2026 Q1?What changed in CTVA's guidance and outlook in FY2026 Q1?Give me the bull and bear case for CTVA after FY2026 Q1 earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

From the prior quarter (Q4 2025), management had described the Bayer settlement as bringing royalty neutrality by 2026. In Q1 2026, management upgraded this to royalty positivity this year, ahead of the prior timeline. The SpinCo was previously unnamed; it is now revealed as Vylor, with proprietary hybrid wheat technology launching next year. A $1.5B discretionary pension contribution was approved to strengthen post-spin capital structure. Q1 EBITDA grew 21% YoY with margins above 29%, while full-year guidance was reaffirmed at $4.0 to $4.2B.

Guidance delta

Full-year 2026 operating EBITDA guidance of $4.0 to $4.2B and margin of 22 to 23% was reaffirmed. The $100M net dis-synergy assumption from the separation remains unchanged. Management noted a approximately $40M oil-price head-impact expected in H2.

Key takeaways

  • Q1 EBITDA grew 21% YoY with margins above 29%, driven by strong seed and crop-protection performance.
  • EPS of $1.50 beat the $1.17 consensus by 28%; revenue of $4.91B exceeded the $4.64B estimate by 5.7%.
  • Full-year 2026 operating EBITDA guidance of $4.0 to $4.2B and 22 to 23% margins reaffirmed.
  • Royalty positivity now expected this year, ahead of the prior royalty-neutral timeline.
  • Separation into Vylor (seed) and standalone crop-protection business on track for Q4, with Form 10 filing by Q2.
  • Board approved $1.5B discretionary pension contribution to strengthen post-spin capital structure.

Management priorities

  • Complete separation and Form 10 filing by Q2, with spin-off in Q4 2026.
  • Launch Vylor brand with proprietary hybrid wheat technology and expand gene-editing capabilities.
  • Expand licensing revenue from Enlist and PowerCore traits to sustain royalty-positive trajectory.
  • Scale biologicals portfolio, including first biocontrol product launch.
  • Advance biofuels initiatives, including sustainable aviation-fuel projects with Bunge, Chevron, and BP JV.

Follow CTVA with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
CTVA EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 3 future estimate-only quarters. Q4 '23 estimate $0.06 Q4 '23 actual $0.15, beat Q1 '24 estimate $0.82 Q1 '24 actual $0.89, beat Q2 '24 estimate $1.73 Q2 '24 actual $1.83, beat Q3 '24 estimate $-0.30 Q3 '24 actual $-0.49, miss Q2 '25 estimate $1.89 Q2 '25 actual $2.20, beat Q3 '25 estimate $-0.51 Q3 '25 actual $-0.23, beat Q4 '25 estimate $0.22 Q4 '25 actual $0.22, match Q1 '26 estimate $1.17 Q1 '26 actual $1.50, beat Q2 '26 estimate $2.24 Q2 '26 actual $2.30, beat Q3 '26 estimate $0.02 Q4 '26 estimate $0.27 Q1 '27 estimate $1.47
Show less

Analyst Consensus ?

ConsensusBuy36 ratings
Bullish2466.7%
Neutral1027.8%
Bearish25.5%

Analyst 52W Price Targets

$11.63Current
$15Low
$62.4Average
$101High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 28, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
UBS Neutral NeutralMaintainOct 12, 2026
Keybanc Overweight Sector WeightUpgradeOct 7, 2026
JP Morgan Overweight NeutralUpgradeOct 6, 2026
Argus Research Buy BuyMaintainSep 18, 2026
Citigroup Neutral NeutralMaintainSep 17, 2026
Show 31 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $11.63. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
UBSAnalyst unavailable$15$12.91 +29.0%Oct 12, 2026
Goldman SachsDuffy Fischer$20$14.45 +72.0%Oct 8, 2026
RBC CapitalArun Viswanathan$17$13.91 +46.2%Oct 7, 2026
KeyBancSalvator Tiano$17$13.91 +46.2%Oct 7, 2026
New StreetAnalyst unavailable$17$11.92 +46.2%Oct 5, 2026
See 66 more

Track every rating change on CTVA the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Corteva, Inc. operates in the agriculture business. The company operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics. This segment also provides digital solutions that assist farmer decision-making with a view to optimize product selection, and maximize yield and profitability.…

Historical context

All CTVA earnings
-11.9%FY2026 Q2 · Calendar Q3 2026+0.1%FY2025 Q4 · Calendar Q1 2026-0.2%FY2025 Q2 · Calendar Q3 2025

Basic Materials peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
JCI Johnson Controls International plc FY2026 Q4 · Calendar Q4 2026 — +5.7% JCI: Record backlog supports FY2027 growth outlook
ECL Ecolab Inc. FY2026 Q3 · Calendar Q4 2026 — +0.8% Ecolab Sustains Growth While Investing in High-Tech Capacity
FCX Freeport-McMoRan Inc. FY2026 Q3 · Calendar Q4 2026 — +1.4% Freeport highlights Grasberg ramp-up and copper growth plans as sales guidance is trimmed
NUE Nucor Corporation FY2026 Q3 · Calendar Q4 2026 -0.7% +5.9% Nucor: Record shipments support strong Q3; CapEx set to moderate
SHW The Sherwin-Williams Company FY2026 Q3 · Calendar Q4 2026 — -2.6% Sherwin-Williams Q3: Growth, Costs and 2027 Savings
CX CEMEX, S.A.B. de C.V. FY2026 Q3 · Calendar Q4 2026 +12.0% -0.1% CEMEX sustains growth while shifting focus to efficiency and asset pruning

Latest beats and misses

Who reports next

Beat on EPS

Missed on EPS

Get the CTVA recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-07-29T18:21:42.696595+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-29T18:21:42.693920+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-07-29. For educational purposes only; not investment advice.